Teva, Sandoz successfully revoke Fibrogen’s patent at EPO
MLex Summary: Fibrogen’s patent on a roxadustat tablet formulation used to treat anemia was revoked by the European Patent Office in a decision published today. The Technical Board of Appeal sided...To view the full article, register now.
Already a subscriber? Click here to view full article